Chemically induced hepatocyte-derived liver progenitors for liver disease: From laboratory research to clinical translation
Chemically induced hepatocyte-derived liver progenitors have emerged as a promising platform for liver regenerative medicine. In 2017, Katsuda et al. demonstrated that a combination of three small molecules—Y-27632, A-83-01, and CHIR99021—could convert mature rodent hepatocytes into proliferative, bipotent liver progenitor cells. Subsequent studies extended this concept to human hepatocytes using modified combinations of small molecules and growth factors, generating expandable progenitor populations with hepatic and biliary differentiation potential. Preclinical studies have demonstrated therapeutic effects of hepatocyte-derived liver progenitors in models of liver fibrosis, cirrhosis, acute liver injury, impaired regeneration, metabolic liver disease, and inherited metabolic disorders. Large-animal studies have further supported their feasibility and safety. More recently, a first-in-human study of human hepatocyte-derived liver progenitors in patients with cirrhosis demonstrated initial safety and feasibility, while an autologous clinical trial has entered recruitment in Japan. Further standardized and controlled clinical studies will be essential to establish the efficacy and long-term safety of these cells and to define their role in future liver regenerative therapies.
Authors
- Yumeng Zhang (ORCID: https://orcid.org/0000-0003-0797-4759)
- Asuma Hata
Institutions
- Hokuto Hospital (JP)
Publication Details
- Published
- 2026-11-22
- DOI
- https://doi.org/10.69854/crm.2026.0064
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00